X-10044A
-1A-
ORAL 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION
This invention provides an improved
5 pharmaceutically elegant tablet formulation of 2-methyl-4-(4-
methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine,
hereinafter referred to as olanzapine, and processes for the
preparation thereof.
10 Olanzapine has shown great promise in the treatment
of psychotic patients and is currently being evaluated for
that purpose. Certain tablet formulations of olanzapine are
known, as described in U.S. Patent No. 5,229,382. However,
improved oral formulations were desired in light of the
15 moisture sensitive, metastable nature of olanzapine, the
tendency of olanzapine to undesirably discolor in the known
tablet formulation, and due to the surprisingly potent nature
of olanzapine.
20 The presently claimed invention provides a
harmaceutically elegant solid oral formulation for
comprising olanzapine intimately mixed with a bulking agent,
binder, disintegrant, a dry binder to provide friability, and
a lubricant; wherein such solid oral formulation is coated
25 with polymer selected from the group consisting of
hydroxypropyl methyl cellulose, hydroxyethyl cellulose,
methylhydroxyethylcellulose, sodium carboxymethylcellulose,
hydroxypropylcellulose, polyvinyl pyrrolidone,
dimethylaminoethyl methacrylatemethylacrylate acid ester
30 copolymer, ethylacrylate-methylmethacrylate copolymer,
methylcellulose, and ethylcellulose.
It is particularly preferred that the polymer coat
does not contain polyethylene glycol.
Further, the invention provides a method for
35 preparing pharmaceutically elegant, stable solid oral
olanzapine formulations having a polymer coat selected from
the group consisting of hydroxypropyl methyl cellulose,
-2-

X-10044A
-2-
hydroxyethyl cellulose, methylhydroxyethylcellulose, sodium
carboxymethylcellulose, hydroxypropylcellulose, polyvinyl
pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate
acid ester copolymer, ethylacrylate-methylmethacrylate
5 copolymer, methylcellulose, and ethylcellulose, comprised of
using a high shear aqueous wet granulation with fluid bed
drying process.
Olanzapine, a potent compound showing promising
10 activity for use in treating psychotic patients, tends to be
metastable, undergo pharmaceutically undesired discoloration,
and demands care to assure homogeniety of the finished solid
formulation.
Applicants have discovered that olanzapine
15 undergoes undesirable discoloration when contacted with
certain excipients including powder blends. Further, the
discoloration is exacerbated by ambient air conditions, at
elevated temperatures, and by moist environments.
Although the discoloration phenomenon does not
20 produce an increase in the number of total related
substances, the browning and mottling appearance is not
generally considered pharmaceutically acceptable for
commercial purposes. Further, the discoloration is
particularly disturbing when a tablet formulation is
2 5 administered to a psychotic patient, which patient may be
especially troubled by the changing appearance of their
medication.
Applicants have discovered that coating the solid
oral formulation with a polymer selected from the group
3 0 consisting of hydroxypropyl methyl cellulose, hydroxyethyl
cellulose, methylhydroxyethylcellulose, sodium
carboxymethylcellulose, hydroxypropylcellulose, polyvinyl
pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate
acid ester copolymer, ethylacrylate-methylmethacrylate
35 copolymer, methylcellulose, and ethylcellulose as a coating
or subcoating provides a uniform, physical stability and
effectively prevents the undesired discoloration phenomenon
-3-

X-10044A
-3-
in the formulation. The formulation is most preferredly in a
tablet form; however, granule formulation and the like are
desired as well.
Most preferred polymer coats are hydroxypropyl
5 methyl cellulose, hydroxypropylcellulose, methylcellulose,
and ethylcellulose. An especially preferred polymer coat is
hydroxypropyl methylcellulose.
It is especially preferred that the formulation
contain the most stable anhydrous form of olanzapine,
10 referred to herein as Form II; however, other forms of
olanzapine are contemplated. Form II has a typical x-ray
powder diffraction pattern as represented by the following
interplanar spacings:
d
10.2689
8.577
7.4721
7.125
6.1459
6.071
5.4849
5.2181
5.1251
4.9874
4.7665
4.7158
4.4787
4.3307
4.22944.141
3.9873

X-10044A
-4-
d
3.7206
3.5645
3.5366
3.3828
3.2516
3.134
3.0848
3.0638
3.0111
2.8739
2.8102
2.7217
2.6432
2.6007
A typical example of an x-ray diffraction pattern
5 for Form II is as follows wherein d represents the
interplanar spacing and I/I1 represents the typical relative
intensities:
d I/Il
10.2689 100.00
8.577 7.96
7.4721 1.41
7.125 6.50
6.1459 3.12
6.071 5.12
5.4849 0.52
5.2181 6.86
5.1251 2.47
4.9874 7.41
4.7665 4.03
4.7158 6.80
4.4787 14.72
4.3307 1.48
-5-

X-10044A
-5-
4.2294 23.19
4.141 11.28
d I/Il
3.9873 9.01
3.7206 14.04
3.5645 2.27
3.5366 4.85
3.3828 3.47
3.2516 1.25
3.134 0.81
3.0848 0.45
3.0638 1.34
3.0111 3.51
2.8739 0.79
2.8102 1.47
2.7217 0.20
2.6432 1.26
2.6007 0.77
The x-ray diffraction patterns set out herein were
obtained using a Siemens D5000 x-ray powder diffractometer
having a copper Kα radiation source of wavelength, λ,=l-54lA.
5 The formulation of the invention preferredly
contains substantially pure Form II as the active ingredient.
As used herein "substantially pure" refers to Form
II associated with less than about 5% undesired polymorphic
form of olanzapine (herein referred to as "Undesired Form"),
10 preferably less than about 2% Undesired Form, and more
preferably less than about 1% Undesired Form. Further,
"substantially pure" Form II will contain less than about
0.5% related substances, wherein "related substances" refers
to undesired chemical impurities or residual solvent or
15 water. In particular, "substantially pure" Form II
prelerably contain less than about 0.05% content of
acetoni trile, more preferably, less than about 0.005% content

X-10044A
-6-
of acetonitrile. Additionally, Form II preferredly contain
less than 0.5% of associated water.
As used herein, the term "mammal" shall refer to
the Mammalia class of higher vertebrates. The term "mammal"
5 includes, but is not limited to, a human. The term
"treating" as used herein includes prophylaxis of the named
condition or amelioration or elimination of the condition
once it has been established.
Form II is the most stable anhydrous form of
10 olanzapine known and is therefore important for the
commercial development of pharmaceutically elegant
formulations. Olanzapine may form an undesired crystal
form in the presence of certain solvents and excipients,
therefore, in making the compositions of the invention it
15 is most desired to prepare the formulation using a method
which does not require dissolution of the olanzapine
substance. The desired Form II can be converted to less
desirable polymorphic forms by contact with methylene
chloride, for example. Additionally, for example,
20 polyethylene glycol contact with the olanzapine substance
produces undesired discoloration, particularly under moist
conditions.
Applicants believe that a dry blend direct
compression process or dry granulated processes for
2 5 preparing solid oral formulations create a greater chance
that poor dose uniformity will occur. In light of the
potent nature of olanzapine, consistent dose uniformity is
imperitive. In accordance with this invention, Applicants
have discovered that a high shear aqueous wet granulation
30 with fluid bed drying is the most effective method for
preparing pharmaceutically elegant, stable, oral olanzapine
formulations.
Uncoated tablets stored at ambient conditions
(approximately 23°C and 40% relative humidity) in amber,
35 high density polyethylene bottles do not show signs of
discoloration after 24 months; however, if the bottle is
-7-

-7-
opened such that the tablets are exposed to open air
ambient conditions then discoloration occurs within 5 days.
A new solid oral formulation was prepared that
used a hydroxypropropyl methylcellulose subcoating and a
5 white color coating. The new formulation did not discolor
after 90 days of open dish storage at 40°C, 60°C, 40°C/75
%RH, ambient temperature with 75% RH, or at ambient
temperature with 85% RH. The hydroxypropyl methylcellulose
coating which is free of polyethylene glycol is much
10 preferred to ensure that discoloration does not occur on
the tablet surface. It provides an effective barrier
between the white color coat which provides an acceptable
medium for imprinting and color dressing of the product.
The hydroxypropylmethylcellulose coating provides
15 sufficient barrier to prevent discoloration attributable to
the polyethylene glycol in the white color coat.
Alternative white film coat formulas containing alternative
plasticizers were evaluated; however, none were able to
prevent discoloration in all test conditions after 90 days
20 of storage. Therefore, the hydroxypropyl methylcellulose
coat or subcoating is a surprising and important component
of pharmaceutically elegant solid oral formulations of
olanzapine.
A diluent or bulking agent should be selected to
2 5 provide an increase in tablet size. The artisan can
utilize known methods to select a bulking agent which
provides hardness, friability, and disintegration time that
is satisfactory for pharmaceutical usage. The bulking
agent should be selected to provide a tablet that has
30 characterstics desired by the patient as well as comply
with applicable regulatory guidelines.
One especially preferred diluent or bulking
agent is lactose. Various forms of lactose are appropriate
for such formulations including anhydrous, hydrous, and
35 spray dried forms. The most desired form of lactose can be
selected based on desired dissolution, content uniformity,
hardness, friability, and disintegration time. The skilled

-8-
artisan is aware of the regulatory requirements for
hardness, friability, and disintegration time and can
adjust the diluent or bulking agents using known techniques
to achieve the desired physical characteristics.
5 The formulation should include a binder for use
in the granulation step. The artisan can choose an
appropriate binder based on the acceptable viscosity, and
desired hydration. Hydroxypropyl cellulose is especially
preferred for use as a binder in the granulation step. The
10 hydroxypropyl cellulose may vary in particle size. Fine
grade hydroxypropyl cellulose is especially preferred for
most claimed formulations.
The desired formulation includes a disintegrant
for use in the granulation as well as in the running
15 powders to facilitate the disintegration process. There
are a variety of grades available, and the grade may be
selected based on the acceptable batch variability. A
particularly prefered disintegrant is crospovidone. A fine
grade of crospovidone provides particularly desirable
20 consistency between batches.
The artisan may choose appropriate dry binders
using known methods. Such binders should be selected to
assure that satisfactory friability is attained. Most
preferably, dry binder is microcrystalline cellulose;
25 however, other appropriate dry binders may be selected.
Such microcrystalline cellulose may be in a granular form.
The artisan can choose an appropriate lubricant
to prevent sticking and picking of the tablets to the
compression tooling. One preferred lubricant is magnesium
30 stearate.
The artisan can readily choose other appropriate
aqueous dispersion film coats (color mix) for application
over the hydroxypropyl methylcellulose layer. Typically,
the color mixture is a dry blend of ingredients which may
35 be dispersed in water and used as an aqueous dispersion to
film coat solid formulations. One example of a typical
color mixture is comprised of hydroxypropyl

X--10044A
-9-
methylcellulose, polyethylene glycol, polysorbate 80, and
titianium dioxide.
A variety of edible inks known to the artisan
are appropriate for imprinting the finished formulation.
5 For example, one typical edible ink is comprised of
shellac, ehtyl alcohol, isopropyl alcohol, n-butyl alcohol,
propylene glycol, ammonium hydroxide, and FD&C Blue.
The solid formulation is most preferably
subcoated with hydroxypropyl methylcellulose, coated with a
10 color coat, and imprinted with an edible ink. The solid
formulation may be polished using standard methods such as
carnauba wax polishing, if desired.
Olanzapine is effective over a wide dosage
range, the actual dose administered being dependent on the
15 condition being treated. For example, in the treatment of
adult humans, dosages of from about 0.25 to 50 mg,
preferably from 1 to 30 mg, and most preferably 1 to 20 mg
per day may be used. A once a day dosage is normally
sufficient, although divided doses may be administered.
20 For treatment of central nervous system disorders, a dose
range of from 1 to 30 mg, preferably 1 to 20 mg per day is
suitable. Radiolabelled Form II 2-methyl-4-(4-methyl-l-
piperazinyl)-lOH-thieno-[2,3-b][1,5]benzodiazepine, can be
detected in the saliva and thus the compound can
25 potentially be monitored in patients to assess compliance.
A preferred formulation of the invention is a
solid oral formulation comprising from about 1 to about 20
mg olanzapine as an active ingedient, wherein such solid
oral formulation is coated with hydroxypropyl
30 methylcellulose. Especially preferred is an oral
formulation comprising from 1 to 20 mg of anhydrous Form II
olanzapine as an effective amount of the active ingredient,
provided that such solid oral formulation is coated with
hydroxypropyl methylcellulose.
35 Most preferably, the solid oral formulation is
contained in packaging materials which protect the
formulation from moisture and light. For example, suitable
-10-

X- 10044A
-10-
packaging materials include amber colored high density
polyethylene bottles, amber colored glass bottles, and other
containers made of a material which inhibits the passage of
light. Most preferably, the packaging will include a
5 desiccant pack. The container may be sealed with an aluminum
foil blister to provide the desired protection and maintain
product stability.
A study of the hydroxypropyl methylcellulose sub-
coated tablets in an amber colored bottle having a desiccant
10 pack stored at harsh, 40°C/75% RH conditions for six months
showed pharmaceutically acceptable stability with a 0.4 % to
about 1.2% increase in total related substances.
The materials for the present invention can be
purchased or prepared by a variety of procedures well known
15 to those of ordinary skill in the art. Olanzapine can be
prepared as described by Chakrabarti in U.S. Patent No
5,229,382 ("382), herein incorporated by reference in its
entirety. It is most desirable to prepare a rapidly
dissolving formulation comprising substantially pure
20 crystalline Form II. Such substantially pure crystalline
Form II olanzapine may be prepared using the techniques
described herein by the Preparation section herein infra.
Compound characterization methods include, for
example, x-ray powder pattern analysis, thermogravimetric
25 analysis (TGA), differential scanning calorimetery (DSC),
titrametric analysis for water, and H1-NMR analysis for
solvent content.
The formulations were studied to assure that the
Form II polymorph was substantially pure using 13C Cross
30 polarization / magic angle spinning (CP/MAS) NMR. Spectra
were obtained using a Varian Unity 400 MHz spectrometer
operating at a carbon frequency of 100.577 MHz and equipped
with a complete solids accessory and Varian 5 mm or 7 mm VT
CP/MAS probes. Measurement conditions were optimized for
35 Olanzapine Form II and were as follows: 90° proton r.f.
pulse 4.5 ms, contact time 1.1 ms, pulse repetition time 5 s,
MAS frequency 7.0 kHz, spectral width 50 kHz, and acquisition
- 11-

X- 10044A
-11-
time 50 ms. Chemical shifts were referenced to the CH3 of
hexamethylbenzene (d = 17.3 ppm) by sample replacement. It
was determined that the substantially pure Form II polymorph
is retained throughout the formulation process claimed
herein. Therefore, the formulations of this invention
provide substantially pure Form II olanzapine polymorph in a
pharmaceutically elegant formulation without producing
undesired polymorphic transformation.
The following examples are provided for purposes of
10 illustration and are not to be construed as limiting the
scope of the claimed invention.
Preparation 1
15 Technical Grade olanzapine

In a suitable three neck flask the following was added:
20
Dimethy sulfoxide (analytical) : 6 volumes
Intermediate 1 : 75 g
N-Methylpiperazine (reagent) : 6 equivalents
Intermediate 1 can be prepared using methods known to the
25 skilled artisan. For example, the preparation of the
Intermediate 1 is taught in the '382 patent.

X- 10044A
-12-
A sub-surface nitrogen sparge line was added to remove the
ammonia formed during the reaction. The reaction was heated
to 120°C and maintained at that temperature throughout the
duration of the reaction. The reactions were followed by
HPLC until < 5% of the intermediate 1 was left unreacted.
After the reaction was complete, the mixture was allowed to
cool slowly to 20°C (about 2 hours). The reaction mixture
was then transferred to an appropriate three neck round
bottom flask and water bath. To this solution with agitation
10 was added 10 volumes reagent grade methanol and the reaction
was stirred at 20°C for 30 minutes. Three volumes of water
was added slowly over about 30 minutes. The reaction slurry
was cooled to zero to 5°C and stirred for 30 minutes. The
product was filtered and the wet cake was washed with chilled
15 methanol. The wet cake was dried in vacuo at 45°C overnight.
The product was identified as technical olanzapine.
Yield: 7 6.7%; Potency: 98.1%
20 Preparation 2
Form II
A 270 g sample of technical grade 2-methyl-4-(4-
methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2 5 was suspended in anhydrous ethyl acetate (2.7 L) . The
mixture was heated to 76°C and maintained at 7 6°C for 30
minutes. The mixture was allowed to cool to 25°C. The
resulting product was isolated using vacuum filtration. The
product was identified as Form II using x-ray powder
3 0 analysis.
Yield: 197 g.
The process described above for preparing Form II
provides a pharmaceutically elegant product having potency ≥
97%, total related substances < 0.5% and an isolated yield of
35 > 73%.
13

X-10044A
-13-
EXAMPLE 1
A portion of the hydroxypropyl cellulose was
dissolved in purified water to form a solution for
5 granulation. The remaining hydroxypropyl cellulose (total of
4.0% w/w final tablet weight), which was an extra fine grade,
was combined with the olanzapine (1.18% w/w), lactose (79.32%
w/w) and a portion of the crospovidone (5% w/w) in a high
shear granulator. All ingredients were security sieved prior
10 to addition and dry blended in the granulator. This mixture
was then granulated with the hydroxypropyl cellulose solution
in the high shear granulator. The granulation was wet sized
using standard methods. The wet granulation was then dried
in a fluidized bed dryer and sized. The material was then
15 added to a tumble bin mixer.
The running powders consisting of microcrystalline cellulose
(granular) (10% w/w), magnesium stearate (0.5% w/w), and the
remainder of the crospovidone were added to the sized
20 granulation. The mixture was blended and compressed with the
appropriate tooling on tablet compression equipment.
Subcoating:
25 Hydroxypropyl methylcellulose (10% w/w) was mixed
with purified water to form a solution. Core tablets were
divided into approximately equal sections and spray coated
with the hydroxypropyl methylcellulose solution . The
operation was performed in a perforated coating pan.
3 0
Coating of Core Tablets:
Color Mixture White (hydroxypropyl methylcellulose,
polyethylene glycol, polysorbate 80, and titanium dioxide)
3 5 was mixed with purified water to form the coating suspension.
Subcoated tablets were divided into approximately equal
sections , and spray coated with the coating suspension

x-10044a
-14-
described above. The operation was performed in a perforated
coating pan.
The coated tablets were lightly dusted with carnauba wax and
5 imprinted with appropriate identification.
EXAMPLE 2
10 The process substantially as described above in
Example 1 was repeated using the following ingredients to
provide pharmaceutically elegant tablet formulations
containing 1, 2.5, 5, 7.5, and 10 mg olanzapine,
respectively, per tablet:
15 1 mG olanzapine per tablet:
Quantity
Names of (mg/tab
Ingredients let)
Active Ingredient
Olanzapine 1.0
Other Ingredients
Lactose 67.43
Hydroxypropyl 3.40
Cellulose
Crospovidone 4.25
Microcrystalline 8.50
Cellulose
Magnesium Stearate 0.42
Subcoating
Hydroxypropyl 1.70
Methylcellulose
Coating
Color Mixture White 3.47
Polishing
Carnauba Wax trace
Imprinting
Edible Blue Ink trace
15

x-10044a
-15-
Olanzapine 2.5 ma Tablets
Quantity
Names of (m g/tab
Ingredients let)
Active Ingredient
Olanzapine 2.5
Other Ingredients
Lactose 102.15
Hydroxypropyl 5.20
Cellulose
Crospovidone 6.50
Microcrystalline 13.00
Cellulose
Magnesium Stearate 0.65
Subcoating
Hydroxypropyl 2.60
Methylcellulose
Coating
Color Mixture White 5.30
Po lishing
Carnauba Wax trace
Imprinting
Edible Blue Ink trace
Olanzapine 5.0 ma Tablets
Quantity
Names of (mg/tab
Ingredients let)
Active Ingredient
Olanzapine 5.00
Other Ingredients
Lactose 156.00
Hydroxypropyl 8.00
Cellulose
Crospovidone 10.00
Microcrystalline 20.00
Cellulose
Magnesium Stearate 1.00
Subcoating
Hydroxypropyl 4.00
Methylcellulose
Coating
Color Mixture White 8.16
Polish ing
Carnauba Wax trace
Imprinting
Edible Blue Ink trace
16

x-10044a
-16-
Olanzapine 7.5 mG Tablets
Quantity
Names of (mg/tab
Ingredients let)
Active Ingredient
Olanzapine 7.50
Other Ingredients
Lactose 234.00
Hydroxypropyl 12.00
Cellulose
Crospovidone 15.00
Microcrystalline 30.00
Cellulose
Magnesium Stearate 1.50
Su bcoating
Hydroxypropyl 6.00
Methylcellulose
Coating
Color Mixture White 12.24
Polishing
Carnauba Wax trace
Imprinting
Edible Blue Ink trace
Olanzapine 10.0 mG Tablets
Quantity
Names of (mg/tab
Ingredients let)
Active Ingredient
Olanzapine 10.00
Other Ingredients
Lactose 312.00
Hydroxypropyl 16.00
Cellulose
Crospovidone 20.00
Microcrystalline 40.00
Cellulose
Magnesium Stearate 2.00
Subcoating
Hydroxypropyl 8.00
Methylcellulose
Coating
Color Mixture White 16.32
Po1ish ing
Carnauba Wax trace
Imprinting
Edible Blue Ink trace
17

Claims
1. A solid oral formulation comprising olanzapine as
an active ingredient intimately mixed with a bulking agent;
binder, disintegrant, a dry binder to assure adequate
friability, and a lubricant; wherein such solid oral formulation
is coated with a polymer selected from the group cosisting of
hydroxypropyl methylcellulose, hydroxyethyl cellulose,
methylhydroxyethylcellulose, sodium carboxymethylcellulose,
hydroxypropylcellulose, polyvinyl pyrrolidone,
dimethylaminoethyl methacrylatemethylacrylate acid ester
copolymer, ethylacrylate-methylmethacrylate copolymer,
methylcellulose, and ethylcellulose.
2. A formulation as claimed by Claim 1 wherein the
polymer coat is selected from the group consisting of
hydroxypropyl methyl cellulose, hydroxypropylcellulose,
methylcellulose, and ethylcellulose
3. A formulation as claimed by Claim 2 wherein the
polymer coat is hydroxypropylmethyl cellulose.
4. A formulation as claimed by any one of Claims 1 to
3 wherein the polymer coat is free of propylene qlycol.
5. A formulation as claimed by Claim 4 wherein the
bulking agent is lactose.
6. A formulation as claimed by Claim 4 wherein the
binder is hydroxypropyl cellulose and the disintegrant is
crospovidone.
7. A formulation as claimed by any one of Claims 1 to
6 wherein the dry binder is microcrystalline cellulose.
8. A formulation as claimed by any one of Claims 1 to
7 wherein the lubricant is magnesium stearate.
9. A formulation as claimed by any one of Claims 1 to
8 wherein the hydroxypropyl methylcellulose is a subcoating
which is further coated with a aqueous dispersion film coat.
-18-

X-10044A
10. A formulation as claimed by Claim 9 wherein the
solid formulation is imprinted using an edible ink.
11. A formulation as claimed by Claim 9 wherein the
formulation comprises from about 1 to about 3 % w/w olanzapine;
from about 69.5 to about 87.5 % w/w lactose; from about 3.5 to
about 4.5 % w/w hydroxypropyl cellulose; from about 4 to about 6
% w/w crospovidone; from about 9 to about 11 % w/w
microcrystalline cellulose; and from about 0.25 to eibout 1 %
magnesium stearate.
12. A formulation as claimed by any one of Claims 1 to
11 wherein the solid formulation is a tablet.
13. A formulation as claimed by Claim 12 v/herein each
tablet provides a dose of olanzapine selected from the group
consisting of 1, 2.5, 5, 7.5, 10, 15, and 20 mg.
14. A formulation as claimed by any one of Claims 1 to
13 wherein olanzapine is substantially pure Form II polymorph
having a typical x-ray powder diffraction pattern as represented
by the following interplanar spacings:
d (A)
10.2689
8.577
7.4721
7.125
6.1459
6.071
5.4849
5.2181
5.1251
4.9874
4.7665
4.7158
4.4787
4.3307
4.2294
4.141
3.9873
3.7206
3.5645
3.5366

3.3828
3.2516
3.134
3.0848
3.0638
3.0111
2.8739
2.8102
2.7217
2.6432
2.6007
15. A process for preparing a stable pharmaceutically
elegant solid oral formulation containing olanzapine as an
active ingredient and having a polymer coating selected from the
group consisting of hydroxypropyl methyl cellulose, hydroxyethyl
cellulose, methylhydroxyethylcellulose, sodium
carboxymethylcellulose, hydroxypropylcellulose, polyvinyl
pyrrolidone, dimethylaminoethyl methacrylatemethylacrylate acid
ester copolymer, ethylacrylate-methylmethacrylate copolymer,
methylcellulose, and ethylcellulose, comprising high shear
aqueous wet granulation with fluid bed drying.
16. A process as claimed by Claim 15 wherein
olanzapine is substantially pure Form II polymorph having a
typical x-ray powder diffraction pattern as represented by the
following interplanar spacings:
d (A)
10.2689
8.577
7.4721
7.125
6.1459
6.071
5.4849
5.2181
5.1251
4.9874
4.7665
4.7158
- 20-

4.4787
4.3307
4.2294
4.141
3.9873
3.7206
3.5645
3.5366
3.3828
3.2516
3.134
3.0848
3.0638
3.0111
2.8739
2.8102
2.7217
2.6432
2.6007
17. A solid oral formulation containing olanzapine
whenever prepared by the process of any one of Claims 15 to 16
18 A solid oral formulation and a process for preparing a stable
pharmaceutically elegant substantially as herein described with reference to
the foregoing examples.
Dated this 7th day of April, 2007
-21-

The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.